MA63538A1 - ISOLATED BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO CD47 AND PD-L1 - Google Patents
ISOLATED BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO CD47 AND PD-L1Info
- Publication number
- MA63538A1 MA63538A1 MA63538A MA63538A MA63538A1 MA 63538 A1 MA63538 A1 MA 63538A1 MA 63538 A MA63538 A MA 63538A MA 63538 A MA63538 A MA 63538A MA 63538 A1 MA63538 A1 MA 63538A1
- Authority
- MA
- Morocco
- Prior art keywords
- bispecific antibody
- pharmaceutical compositions
- specifically binding
- antibody specifically
- disorders mediated
- Prior art date
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 title abstract 5
- 108010074708 B7-H1 Antigen Proteins 0.000 title abstract 5
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 title abstract 5
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention relève du domaine de la biotechnologie et de la médecine, et concerne en particulier un anticorps bispécifique qui se lie de manière spécifique à CD47 et PD-L1. L'invention concerne en outre un acide nucléique codant pour ledit anticorps bispécifique, un vecteur d'expression, une cellule hôte pour produire ledit anticorps bispécifique et un procédé de production de ladite cellule, des compositions pharmaceutiques comprenant l'anticorps bispécifique selon l'invention, des compositions pharmaceutiques comprenant l'anticorps bispécifique selon l'invention et d'autres composés thérapeutiquement actifs, des méthodes de traitement de maladies ou de troubles médiés par CD47 et PD-L1, l'utilisation de l'anticorps bispécifique ou des compositions pharmaceutiques de celui-ci pour le traitement de maladies ou de troubles médiés par CD47 et PD-L1, et l'utilisation de l'anticorps bispécifique selon l'invention et d'autres composés thérapeutiquement actifs pour le traitement de maladies ou de troubles médiés par CD47 et PD-L1.The present invention relates to the field of biotechnology and medicine, and in particular relates to a bispecific antibody that specifically binds to CD47 and PD-L1. The invention further relates to a nucleic acid encoding said bispecific antibody, an expression vector, a host cell for producing said bispecific antibody and a method for producing said cell, pharmaceutical compositions comprising the bispecific antibody according to the invention, pharmaceutical compositions comprising the bispecific antibody according to the invention and other therapeutically active compounds, methods of treating diseases or disorders mediated by CD47 and PD-L1, the use of the bispecific antibody or pharmaceutical compositions thereof for the treatment of diseases or disorders mediated by CD47 and PD-L1, and the use of the bispecific antibody according to the invention and other therapeutically active compounds for the treatment of diseases or disorders mediated by CD47 and PD-L1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2021118025A RU2815823C2 (en) | 2021-06-21 | Isolated bispecific antibody that specifically binds to cd47 and pd-l1 | |
| PCT/RU2022/050195 WO2022271053A1 (en) | 2021-06-21 | 2022-06-21 | Isolated bispecific antibody that specifically binds to cd47 and pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA63538A1 true MA63538A1 (en) | 2024-09-30 |
Family
ID=84544589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA63538A MA63538A1 (en) | 2021-06-21 | 2022-06-21 | ISOLATED BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO CD47 AND PD-L1 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4359445A1 (en) |
| CN (1) | CN117858904A (en) |
| AR (1) | AR126185A1 (en) |
| BR (1) | BR112023026982A2 (en) |
| CL (1) | CL2023003854A1 (en) |
| CO (1) | CO2023018165A2 (en) |
| CR (1) | CR20230612A (en) |
| EC (1) | ECSP23097121A (en) |
| MA (1) | MA63538A1 (en) |
| MX (1) | MX2024000266A (en) |
| PE (1) | PE20250352A1 (en) |
| TW (1) | TW202306998A (en) |
| WO (1) | WO2022271053A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019068302A1 (en) * | 2017-10-03 | 2019-04-11 | Закрытое Акционерное Общество "Биокад" | Antibodies specific to cd47 and pd-l1 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2622097T3 (en) * | 2009-07-24 | 2017-07-05 | Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | Procedure for the development of a liquid composition to be applied as a foam on the skin as well as a composition that can be applied topically |
| RU2665790C1 (en) * | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Monoclonal pd-l1 antibody |
-
2022
- 2022-06-21 MA MA63538A patent/MA63538A1/en unknown
- 2022-06-21 AR ARP220101614A patent/AR126185A1/en unknown
- 2022-06-21 CN CN202280044514.XA patent/CN117858904A/en active Pending
- 2022-06-21 EP EP22828864.3A patent/EP4359445A1/en active Pending
- 2022-06-21 TW TW111123100A patent/TW202306998A/en unknown
- 2022-06-21 MX MX2024000266A patent/MX2024000266A/en unknown
- 2022-06-21 BR BR112023026982A patent/BR112023026982A2/en unknown
- 2022-06-21 PE PE2023003437A patent/PE20250352A1/en unknown
- 2022-06-21 WO PCT/RU2022/050195 patent/WO2022271053A1/en active Application Filing
- 2022-06-21 CR CR20230612A patent/CR20230612A/en unknown
-
2023
- 2023-12-21 CO CONC2023/0018165A patent/CO2023018165A2/en unknown
- 2023-12-21 CL CL2023003854A patent/CL2023003854A1/en unknown
- 2023-12-27 EC ECSENADI202397121A patent/ECSP23097121A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019068302A1 (en) * | 2017-10-03 | 2019-04-11 | Закрытое Акционерное Общество "Биокад" | Antibodies specific to cd47 and pd-l1 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117858904A (en) | 2024-04-09 |
| EP4359445A1 (en) | 2024-05-01 |
| PE20250352A1 (en) | 2025-02-06 |
| CR20230612A (en) | 2024-07-29 |
| TW202306998A (en) | 2023-02-16 |
| CO2023018165A2 (en) | 2024-05-30 |
| WO2022271053A1 (en) | 2022-12-29 |
| BR112023026982A2 (en) | 2024-03-12 |
| CL2023003854A1 (en) | 2024-07-19 |
| AR126185A1 (en) | 2023-09-27 |
| MX2024000266A (en) | 2024-01-31 |
| ECSP23097121A (en) | 2024-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52288B1 (en) | METHYL-MODIFYING ENZYME MODULATORS, COMPOSITIONS AND USES THEREOF | |
| MA32928B1 (en) | ANTI-CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER | |
| MA33607B1 (en) | BISPECIFIC BINDING MOLECULES FOR ANTI-ANGIOGENIC THERAPY | |
| MA49599B1 (en) | Antibodies specific to cd47 and pd-l1 | |
| MA47079B1 (en) | Amino-triazolopyidin compounds and their use to treat cancer | |
| Hao et al. | Odanacatib, A cathepsin K‐specific inhibitor, inhibits inflammation and bone loss caused by periodontal diseases | |
| MA32300B1 (en) | Humanizing anti-factor antibodies and uses thereof | |
| MA46665B1 (en) | Cyclic peptide tyrosine tyrosine compounds coupled to antibody as neuropeptide y receptor modulators | |
| MA47392B1 (en) | Bis-octahydrophenanthrene carboxamides and their protein conjugates | |
| MA35728B1 (en) | Derivatives of 6,7-dihydro-5h-benzo [7] annulene, process for their preparation, pharmaceutical preparations containing them and their use in the manufacture of pharmaceutical products | |
| MA38099A1 (en) | New compounds triazolopyrazines substituted brd4 inhibitors | |
| Su et al. | Oral Treponema denticola Infection Induces Aβ 1–40 and Aβ 1–42 Accumulation in the Hippocampus of C57BL/6 Mice | |
| MA42397B1 (en) | Substituted 4-azaindoles and their use as modulators of the glun2b receptor | |
| MA34175B1 (en) | HUMANIZED ANTI-CXCR4 ANTIBODIES FOR THE TREATMENT OF CANCER | |
| MA34333B1 (en) | 6,7-DIHYDRO-5H-BENZO [7] ANNULENE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL PRODUCTS | |
| MA44950B1 (en) | Composition, in particular preventive and curative pharmaceutical composition, based on peroxometallate | |
| Purwaningrum et al. | Dissecting specific Wnt components governing osteogenic differentiation potential by human periodontal ligament stem cells through interleukin-6 | |
| MA58646A1 (en) | TUBULYSINS AND TUBULYSIN-PROTEIN CONJUGATES | |
| WO2023159148A3 (en) | Inhibitors of nlrp3 | |
| MA63538A1 (en) | ISOLATED BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO CD47 AND PD-L1 | |
| MA62715B1 (en) | MONOCLONAL ANTIBODY BINDING SPECIFICALLY TO GD2 | |
| Young et al. | Sperm can act as vectors for HIV‐1 transmission into vaginal and cervical epithelial cells | |
| Zhang et al. | Plasma membrane proteomic profile discovers macrophage-capping protein related to latent HIV-1 | |
| FR3098714B1 (en) | Process for treating keratin fibers combining a composition comprising a water-soluble silicate and a composition comprising an amino acid and / or an oligopeptide | |
| Yu et al. | Effects of G-CSF on hPDLSC proliferation and osteogenic differentiation in the LPS-induced inflammatory microenvironment |